NEW YORK (GenomeWeb News) — Florida Atlantic University and Torrey Pines Institute for Molecular Studies plan to study compounds discovered by TPIMS with an FAU genetic discovery related to three major cancers, FAU said yesterday.
Under the agreement, FAU and TPIMS will use a gene called SIM2, which has been associated with colon, prostate, and pancreatic cancers, at FAU’s Charles E. Schmidt College of Science to develop drugs.
FAU said researchers at the CSCS have co-developed an assay to discover an inhibitor of the SIM2 gene, which will be screened against “thousands of compounds from TPIMS’ collection” for usefulness as a therapy.
FAU said the researchers will use Affymetrix’s GeneChip microarrays for the analysis.
According to CSCS, FAU “has the basic research and proof-of-concept in place,” and TPIMS has “the compounds and expertise to help expedite drug discovery.”